Evidence map›Paper›PMID 42604730›Full record

ArticleBritish journal of haematology2026

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

Hanny Al-Samkari, Filip Matthijssens, Kaichi Nishiwaki, Francesco Zaja, Sylvian Audia, Yoshitaka Miyakawa, Jaume Ayguasanosa, Damien Chimits, Anna Hultberg, Peter Ulrichts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanny Al-SamkariDivision of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6175-1383
Filip Matthijssensargenx, Ghent, Belgium.
Kaichi NishiwakiDepartment of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.
Francesco ZajaDipartimento Clinico di Scienze Mediche, Università degli Studi di Trieste, Trieste, Italy.ORCID https://orcid.org/0000-0003-3995-8817
Sylvian AudiaDepartment of Internal Medicine and Clinical Immunology, Université Bourgogne Europe, CHU Dijon-Bourgogne, Constitutive Referral Centre for Adult Autoimmune Cytopenia, Dijon, France.
Yoshitaka MiyakawaDepartment of Hematology, Saitama Medical University Hospital, Saitama, Japan.
Jaume Ayguasanosaargenx, Ghent, Belgium.
Damien Chimitsargenx, Ghent, Belgium.
Anna Hultbergargenx, Ghent, Belgium.
Peter Ulrichtsargenx, Ghent, Belgium.

Funding

Argenx
6 · The paper itself

Abstract

Elevated percentage of immature platelets is indicative of consumptive thrombocytopenic disorders. In immune thrombocytopenia, low platelet counts may result from reduced production or increased degradation, both driven by IgG autoantibodies. By blocking FcRn, efgartigimod decreases immature platelet fraction, likely by reducing platelet degradation through decreased IgG autoantibody levels.

Indexed as

Blood PlateletsPurpura, Thrombocytopenic, IdiopathicAutoantibodiesHumansImmunoglobulin GPlatelet CountAutoantibodiesImmunoglobulin Gclinical trialimmune thrombocytopeniaplatelets

Identifiers

PMID42604730
PMCPMC13674184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.